TME Pharma N.V.

Description

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. The company's lead asset, NOX-A12, has shown excellent results in newly diagnosed chemotherapy-refractory glioblastoma patients, nearly doubling median survival vs. a standard of care reference cohort of matched patients. The company's plans to externalize and monetize its second clinical-stage asset in ophthalmology.

Company members

Aram Mangasarian, CEO

HealthTech Innovation Days - 6th edition is an event organized by HealthTech For Care.

HealthTech For Care is an endowment fund (non-for profit organization) whose primary mission is to advocate for universal access to healthcare for all European patients, with a specific focus on advanced medical technologies and innovative drugs. The fund's initiatives and events with a European dimension gather all stakeholders involved in the health innovation value chain, fostering better coordination within the European health ecosystem. HealthTech For Care is administered by a board of European experts.

For any request: contact@htfc-eu.com
Where to find us? Healthtech For Care, 10 Place de Catalogne, 75014 Paris

TME Pharma N.V.

Description

Company members

© HealthTech For Care 2022-2024 - All rights reserved

Cookies Policy

Legal notice

Privacy Policy